On February 6, 2023 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in the following investor conferences in February 2023 (Press release, MacroGenics, FEB 6, 2023, View Source [SID1234626881]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks | Oncology Day (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Thursday, February 9, 2023, at 2:45 pm ET. MacroGenics’ management will also participate in one-on-one meetings.
SVB Securities Global Biopharma Conference (Virtual). Scott Koenig, M.D., Ph.D., will participate in a formal presentation session with a SVB Securities research analyst on Tuesday, February 14, 2023, at 3:00 pm ET. MacroGenics’ management will also participate in one-on-one meetings.
A webcast of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain an archived replay of this webcast on its website for 30 days.